Antigen-Specific T Cell Responses in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) has a relatively high antigenicity and immunogenicity. In the past 10–15 years, several tumor-associated antigens (TAAs) and their T cell epitopes for HCC have been identified and studied to understand the immune responses in HCC patients. In addition, these TAAs and epitopes have been used for the development of immunotherapy of HCC. Recent clinical studies using peptide vaccines suggest that, while the efficacy against advanced cancers may be limited when used alone, they have a significant potential to prevent tumor recurrence, and to prolong survival and time-to-progression. Further development of immunotherapy in HCC will depend on the identification of highly immunogenic antigen-derived T cell epitopes, such as neoantigens, as well as a better understanding of the mechanisms underlying antitumor immunity.
KeywordsEpitope Cytotoxic T lymphocyte Cancer Peptide vaccine Immunotherapy
Conflict of Interest
The authors disclose no conflicts of interest.
- 26.Nakamoto Y, Mizukoshi E, Kitahara M, Arihara F, Sakai Y, Kakinoki K, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol. 2011;163:165–77.CrossRefPubMedPubMedCentralGoogle Scholar